Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PI3K/mTOR inhibitor CLL442

A topical inhibitor of class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR), with potential antineoplastic activity. Upon topical administration, PI3K/mTOR inhibitor CLL442 targets and inhibits class I PI3K isoforms and mTOR kinase. This disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, survival and motility.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	CLL 442 CLL-442 CLL442

PI3K/mTOR inhibitor CLL442

Search NCI's Drug Dictionary